#### **DUBIN THOMAS I H**

Form 4

October 28, 2010

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**OMB** 

**OMB APPROVAL** 

Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

**SECURITIES** Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations

may continue. See Instruction

(Print or Type Responses)

1(b).

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person \* **DUBIN THOMAS I H** 

2. Issuer Name and Ticker or Trading

Symbol

ALEXION PHARMACEUTICALS INC [ALXN]

Issuer

(Check all applicable)

(Last)

(First)

(Middle)

(Zip)

3. Date of Earliest Transaction

(Month/Day/Year) 10/26/2010

Director 10% Owner X\_ Officer (give title Other (specify

5. Relationship of Reporting Person(s) to

below) SVP & Chief Legal Officer

C/O ALEXION PHARMACEUTICALS INC, 352

KNOTTER DRIVE

(Street)

(State)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

CHESHIRE, CT 06410

1.Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) (Instr. 3)

Execution Date, if (Month/Day/Year)

3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)

(A)

(D)

5. Amount of Securities Beneficially Owned Following

Ownership Form: Direct (D) or Indirect (I)

7. Nature of Indirect Beneficial Ownership (Instr. 4)

Reported (Instr. 4) Transaction(s)

(Instr. 3 and 4)

Common

(City)

Stock, par value 10/26/2010 \$.0001 per

M 20,000

Code V Amount

42,810

Price

D

Common

Stock, par

10/26/2010

M 10 \$ 10.5 42,820

D

share

value

\$.0001 per share

1

### Edgar Filing: DUBIN THOMAS I H - Form 4

Common							
Stock, par					\$		
value	10/26/2010	S	20,010	D	67.79	22,810	D
\$.0001 per					(1)		
share							

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	\$ 17.69	10/26/2010		S		20,000	05/09/2001	02/09/2011	Common Stock, par value \$.0001 per share	20,000
Option to Purchase Common Stock	\$ 10.5	10/26/2010		S		10	09/14/2001	06/14/2011	Common Stock, par value \$.0001 per share	10

# **Reporting Owners**

Relationships **Reporting Owner Name / Address** Director 10% Owner Officer Other

**DUBIN THOMAS I H** C/O ALEXION PHARMACEUTICALS INC 352 KNOTTER DRIVE CHESHIRE, CT 06410

SVP & Chief Legal Officer

Reporting Owners 2

## **Signatures**

/s/ Thomas Dubin 10/28/2010

\*\*Signature of Date
Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$67.75 \$67.86. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3